Myeloma Minute
Publicado: Vie Ago 26, 2011 7:40 am
International myeloma foundation
Myeloma minute
26/08/2011
Cita:
"Welcome to the IMF's Myeloma Minute
News about myeloma treatment, research, support and the myeloma community
from the International Myeloma Foundation.
* What's News
* Advocacy Updates
* What's New in Research
WHAT'S NEWS
IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published this month in the Clinical Journal of Oncology Nursing.
Patients with myeloma are survivng longer and, therefore, may experience continuing effects of their disease and treatment. Through clinical experience, the NLB was aware that a specific set of needs exists in this patient population. Identification of these needs, and stressing the importance of prompt intervention, could lead to improvement in their quality of life and overall survival.
http://myeloma.org/ArticlePage.action?t ... goryId=429
Tonight! Living Well with Myeloma teleconference on drug interactions and contra-indications.
http://myeloma.org/ArticlePage.action?t ... 76&aTab=-1
August 25, 2011 from 4:00 - 5:00 PM PT. This teleconference will feature Timothy Tyler, PharmD, FCSHP, Director of Pharmacy Services for Aptium Oncology.
Win a Dream Vacation to Costa Rica!
https://online.myeloma.org/netcommunity/myeloma200
Help the IMF reach its goal of $200,000 for our Research, Education, Support and Advocacy Programs by participating in Myeloma 200 - Closer to a Cure! and be entered into a drawing for a trip for two for 7 days and 6 nights to the beautiful Four Seasons Costa Rica, including airfare and a $400 gift certificate toward spa treatments.
Save the Date! Sept. 8th at 4:00PM PST/7:00PM EST. A teleconference with Dr. Durie on the the importance of clinical trial participation.
Dr. Durie will review the ASPIRE trial as an example. The ASPIRE trial is a Phase 3 study evaluating carfilzomib in combination with Revlimid and low dose dexamethasone vs. Revdex alone. You won't want to miss this!
Researchers develop culture method for blood stem cells
Researchers from the University of Texas Southwestern Medical Center have developed a culture method that allowed for transplanted adult blood stem cells not to be attacked by the immune system. (from Xinhuanet.com)
http://news.xinhuanet.com/english2010/h ... 030163.htm
Modified Form of Ecstasy Developed to Treat Cancer
Modified forms of the dance club drug may be effective against blood cancers such as leukaemia, lymphoma and myeloma, early research suggests. Researchers at the University of Birmingham, UK have now revealed that specially modified forms of ecstasy boosted the drug's ability to destroy cancerous cells 100 times. Further work could lead to MDMA-derivatives being used in patient trials. (from the UK Press Association)
http://www.google.com/hostednews/ukpres ... 652111045A
The Summer 2011 issue of Myeloma Today is on the web!
Articles include:
* Current Role of Serum Free Light Chain Analysis in Myeloma
* Long-Term Survivorship Guidelines for Multiple Myeloma Patients
* Treating Spinal Fractures with Balloon Kyphoplasty
http://myeloma.org/ArticlePage.action?t ... 58&aTab=-1
New Understanding Protein Electrophoresis on the web
Updated Editions of "Understanding Velcade," "Understanding Anemia and Fatigue," " Understanding Bisphosphonate Therapy," "Understanding Serum Free Light Chain Assays" and Understanding Stem Cell Transplant" have also been posted.
http://myeloma.org/IndexPage.action?tab ... egoryId=72
Second Primary Malignancies Explored in Multiple Myeloma
Three randomized controlled trials presented at the 2010 Annual Meeting of the American Society of Hematology (ASH) suggested that treating multiple myeloma with lenalidomide increased the risk of second primary malignancies. At the ASCO Annual Meeting in June, additional studies that explored this issue suggested that the risk of second primary malignancies in this setting is low and the benefits of lenalidomide seem to outweigh the risks, but a number of questions remain unresolved. (from ASCOPost)
http://www.ascopost.com/articles/august ... eloma.aspx
Expert Point of View: Second Primary Malignancies Explored in Multiple Myeloma
Ola Landgren, MD, PhD, Chief of the Multiple Myeloma Section at NCI, and member of the International Myeloma Working Group, had some additional comments about the ASCO presentations on second primary malignancies in lenalidomide-treated patients. He said that the reporting of second primaries has several limitations that patients and doctors need to be aware of. (from ASCOPost)
http://www.ascopost.com/articles/august ... eloma.aspx
ASCO: Multiple Myeloma Antibody Tx Waits in Wings
Medical science may be on the verge of finding antibody-based treatments for multiple myeloma, although they are likely to be used in combination with other types of therapy. (from MedPage Today)
http://www.medpagetoday.com/MeetingCoverage/ASCO/26861
UPDATE 1-Study: Cancer drugs approved in US before Europe
Findings released on Thursday counter a common belief among doctors, academics and investors that new oncology drugs often win approval in Europe first, said researchers from the nonprofit advocacy group Friends of Cancer Research. (from Reuters Africa)
http://af.reuters.com/article/mauritani ... 16?sp=true
PRO/CON: Should All Eligible Patients with Multiple Myeloma Receive Autologous Stem-cell Transplant as Part of Initial Treatment?
Philippe Moreau, MD, and S. Vincent Rajkumar, MD, discuss the pros and cons of all eligible patients with multiple myeloma receiving autologous stem-cell transplant as part of initial treatment. (from ASCOPost)
http://www.ascopost.com/articles/may-15 ... eloma.aspx
Firefighters call for cancer compensation
In 2009, after 26 years of fighting fires, the 51-year-old father of four, Ross Lindley, was diagnosed with multiple myeloma, or cancer of the bone marrow, which is linked to chemical exposure. Mr Lindley says his medical bills have run into the hundreds of thousands of dollars but although his job regularly exposed him to carcinogenic chemicals, he was never compensated. (from the Sydney Morning Herald)
http://news.smh.com.au/breaking-news-na ... 1g5h2.html
Fin de la cita
Para los que nececitan traduccion:
http://translate.google.es/
Un abrazo
Myeloma minute
26/08/2011
Cita:
"Welcome to the IMF's Myeloma Minute
News about myeloma treatment, research, support and the myeloma community
from the International Myeloma Foundation.
* What's News
* Advocacy Updates
* What's New in Research
WHAT'S NEWS
IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published this month in the Clinical Journal of Oncology Nursing.
Patients with myeloma are survivng longer and, therefore, may experience continuing effects of their disease and treatment. Through clinical experience, the NLB was aware that a specific set of needs exists in this patient population. Identification of these needs, and stressing the importance of prompt intervention, could lead to improvement in their quality of life and overall survival.
http://myeloma.org/ArticlePage.action?t ... goryId=429
Tonight! Living Well with Myeloma teleconference on drug interactions and contra-indications.
http://myeloma.org/ArticlePage.action?t ... 76&aTab=-1
August 25, 2011 from 4:00 - 5:00 PM PT. This teleconference will feature Timothy Tyler, PharmD, FCSHP, Director of Pharmacy Services for Aptium Oncology.
Win a Dream Vacation to Costa Rica!
https://online.myeloma.org/netcommunity/myeloma200
Help the IMF reach its goal of $200,000 for our Research, Education, Support and Advocacy Programs by participating in Myeloma 200 - Closer to a Cure! and be entered into a drawing for a trip for two for 7 days and 6 nights to the beautiful Four Seasons Costa Rica, including airfare and a $400 gift certificate toward spa treatments.
Save the Date! Sept. 8th at 4:00PM PST/7:00PM EST. A teleconference with Dr. Durie on the the importance of clinical trial participation.
Dr. Durie will review the ASPIRE trial as an example. The ASPIRE trial is a Phase 3 study evaluating carfilzomib in combination with Revlimid and low dose dexamethasone vs. Revdex alone. You won't want to miss this!
Researchers develop culture method for blood stem cells
Researchers from the University of Texas Southwestern Medical Center have developed a culture method that allowed for transplanted adult blood stem cells not to be attacked by the immune system. (from Xinhuanet.com)
http://news.xinhuanet.com/english2010/h ... 030163.htm
Modified Form of Ecstasy Developed to Treat Cancer
Modified forms of the dance club drug may be effective against blood cancers such as leukaemia, lymphoma and myeloma, early research suggests. Researchers at the University of Birmingham, UK have now revealed that specially modified forms of ecstasy boosted the drug's ability to destroy cancerous cells 100 times. Further work could lead to MDMA-derivatives being used in patient trials. (from the UK Press Association)
http://www.google.com/hostednews/ukpres ... 652111045A
The Summer 2011 issue of Myeloma Today is on the web!
Articles include:
* Current Role of Serum Free Light Chain Analysis in Myeloma
* Long-Term Survivorship Guidelines for Multiple Myeloma Patients
* Treating Spinal Fractures with Balloon Kyphoplasty
http://myeloma.org/ArticlePage.action?t ... 58&aTab=-1
New Understanding Protein Electrophoresis on the web
Updated Editions of "Understanding Velcade," "Understanding Anemia and Fatigue," " Understanding Bisphosphonate Therapy," "Understanding Serum Free Light Chain Assays" and Understanding Stem Cell Transplant" have also been posted.
http://myeloma.org/IndexPage.action?tab ... egoryId=72
Second Primary Malignancies Explored in Multiple Myeloma
Three randomized controlled trials presented at the 2010 Annual Meeting of the American Society of Hematology (ASH) suggested that treating multiple myeloma with lenalidomide increased the risk of second primary malignancies. At the ASCO Annual Meeting in June, additional studies that explored this issue suggested that the risk of second primary malignancies in this setting is low and the benefits of lenalidomide seem to outweigh the risks, but a number of questions remain unresolved. (from ASCOPost)
http://www.ascopost.com/articles/august ... eloma.aspx
Expert Point of View: Second Primary Malignancies Explored in Multiple Myeloma
Ola Landgren, MD, PhD, Chief of the Multiple Myeloma Section at NCI, and member of the International Myeloma Working Group, had some additional comments about the ASCO presentations on second primary malignancies in lenalidomide-treated patients. He said that the reporting of second primaries has several limitations that patients and doctors need to be aware of. (from ASCOPost)
http://www.ascopost.com/articles/august ... eloma.aspx
ASCO: Multiple Myeloma Antibody Tx Waits in Wings
Medical science may be on the verge of finding antibody-based treatments for multiple myeloma, although they are likely to be used in combination with other types of therapy. (from MedPage Today)
http://www.medpagetoday.com/MeetingCoverage/ASCO/26861
UPDATE 1-Study: Cancer drugs approved in US before Europe
Findings released on Thursday counter a common belief among doctors, academics and investors that new oncology drugs often win approval in Europe first, said researchers from the nonprofit advocacy group Friends of Cancer Research. (from Reuters Africa)
http://af.reuters.com/article/mauritani ... 16?sp=true
PRO/CON: Should All Eligible Patients with Multiple Myeloma Receive Autologous Stem-cell Transplant as Part of Initial Treatment?
Philippe Moreau, MD, and S. Vincent Rajkumar, MD, discuss the pros and cons of all eligible patients with multiple myeloma receiving autologous stem-cell transplant as part of initial treatment. (from ASCOPost)
http://www.ascopost.com/articles/may-15 ... eloma.aspx
Firefighters call for cancer compensation
In 2009, after 26 years of fighting fires, the 51-year-old father of four, Ross Lindley, was diagnosed with multiple myeloma, or cancer of the bone marrow, which is linked to chemical exposure. Mr Lindley says his medical bills have run into the hundreds of thousands of dollars but although his job regularly exposed him to carcinogenic chemicals, he was never compensated. (from the Sydney Morning Herald)
http://news.smh.com.au/breaking-news-na ... 1g5h2.html
Fin de la cita
Para los que nececitan traduccion:http://translate.google.es/
Un abrazo
Mañana mas..
Y sigue asi:
No se trata de leer todo eso..sino de leer soló los articulos que a cada uno nos puedan interesar...